


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**CERTIFICATE OF EXPRESS MAILING**

I certify that the documents referred to as enclosed herein are being deposited on December 2, 2005, with the U.S. Postal Service as Express Mail No. EV494042365US under 37 C.F.R. 1.10 and are addressed to MAIL STOP RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

  
Charles P. Romano  
Registration No. 56,991

|                        |                                       |                             |                        |
|------------------------|---------------------------------------|-----------------------------|------------------------|
| <b>Application of:</b> | Mueckler et al.                       | <b>Group Art Unit:</b>      | 1651                   |
| <b>Serial No.:</b>     | 10/621,485                            | <b>Atty. Docket No.:</b>    | 56029-41936            |
| <b>Filed:</b>          | July 16, 2003                         | <b>Examiner:</b>            | Fernandez, Susan Emily |
| <b>For:</b>            | Cell Free Assay for Insulin Signaling | <b>Confirmation Number:</b> | 3332                   |

MAIL STOP RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT AND RESPONSE WITH RCE**

In response to the Advisory Action of October 31, 2005, the following amendments and remarks are submitted together with a Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

It is not believed that extensions of time are required beyond those which may otherwise be provided for in documents accompanying this Response. However, in the event that additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned for under 37 C.F.R. §1.136(a), and any fees required therefore are hereby authorized to be charged to our Deposit Account 20-0823.

**Amendment of the claims** are reflected in the listing of claims which begin on page 2 of this paper.

**Amendments to the specification** begin on page 5

**Remarks** begin on page 7 of this paper.